https://spypharm.com/rss/latest-posts SpyPharm | Pharmaceutical News, Developments & Trends & Latest Posts en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/almirall-completes-eu-regulatory-procedure-for-antifungal-jublia https://spypharm.com/almirall-completes-eu-regulatory-procedure-for-antifungal-jublia Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/parenteral-solutions-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/parenteral-solutions-in-contract-manufacturing-for-the-pharmaceutical-industry Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/the-growing-role-of-cdmos-in-the-circular-economy https://spypharm.com/the-growing-role-of-cdmos-in-the-circular-economy Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/hanmi-and-medic-ink-cancer-biomarker-collaboration-deal https://spypharm.com/hanmi-and-medic-ink-cancer-biomarker-collaboration-deal Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/digital-twins-a-new-path-to-personalised-medicine https://spypharm.com/digital-twins-a-new-path-to-personalised-medicine Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/the-science-of-viscous-drug-product-filling-pumps-pressure-and-process-optimization https://spypharm.com/the-science-of-viscous-drug-product-filling-pumps-pressure-and-process-optimization Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/lilly-touts-omvohs-superiority-over-jjs-stelara-in-crohns https://spypharm.com/lilly-touts-omvohs-superiority-over-jjs-stelara-in-crohns Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/bayer-applies-for-eu-approval-of-menopause-drug-elinzanetant https://spypharm.com/bayer-applies-for-eu-approval-of-menopause-drug-elinzanetant Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/transgenes-stock-drops-after-phase-ii-cancer-jab-trial-misses-primary-endpoint https://spypharm.com/transgenes-stock-drops-after-phase-ii-cancer-jab-trial-misses-primary-endpoint Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/gitex-global-2024-huawei-launches-a-series-of-industrial-digital-and-intelligent-transformation-solutions-and-flagship-products https://spypharm.com/gitex-global-2024-huawei-launches-a-series-of-industrial-digital-and-intelligent-transformation-solutions-and-flagship-products Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing https://spypharm.com/cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing Mon, 14 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/developments-in-rna-research-win-nobel-prizes-for-the-second-consecutive-year https://spypharm.com/developments-in-rna-research-win-nobel-prizes-for-the-second-consecutive-year Sun, 13 Oct 2024 04:00:13 -0400 spectro https://spypharm.com/talk-of-vaccine-schedule-revision-amidst-research-showing-waning-efficacy-of-gsks-rsv-vaccine https://spypharm.com/talk-of-vaccine-schedule-revision-amidst-research-showing-waning-efficacy-of-gsks-rsv-vaccine Sun, 13 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/maven-clinic-receives-125-million-to-fund-technology-and-value-based-treatment https://spypharm.com/maven-clinic-receives-125-million-to-fund-technology-and-value-based-treatment Sun, 13 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/the-medical-device-sectors-surging-regulatory-burden-how-are-suppliers-coping https://spypharm.com/the-medical-device-sectors-surging-regulatory-burden-how-are-suppliers-coping Sun, 13 Oct 2024 04:00:05 -0400 spectro https://spypharm.com/cphi-europe-targeting-supply-chain-bottlenecks-key-for-cell-and-gene-therapies https://spypharm.com/cphi-europe-targeting-supply-chain-bottlenecks-key-for-cell-and-gene-therapies Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/xtalpis-ai-biologics-discovery-platform-licensed-to-janssen-biotech https://spypharm.com/xtalpis-ai-biologics-discovery-platform-licensed-to-janssen-biotech Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/activist-investor-starboard-cries-foul-play-in-exec-u-turn-at-pfizer https://spypharm.com/activist-investor-starboard-cries-foul-play-in-exec-u-turn-at-pfizer Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/booster-therapeutics-to-develop-proteasome-activator-medicines https://spypharm.com/booster-therapeutics-to-develop-proteasome-activator-medicines Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/keybioscience-and-eli-lilly-extend-partnership-for-obesity-treatments https://spypharm.com/keybioscience-and-eli-lilly-extend-partnership-for-obesity-treatments Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cphi-europe-overcoming-the-unique-challenges-with-high-concentration-mabs https://spypharm.com/cphi-europe-overcoming-the-unique-challenges-with-high-concentration-mabs Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/south-korean-company-dong-a-st-wins-fda-approval-for-stelara-biosimilar https://spypharm.com/south-korean-company-dong-a-st-wins-fda-approval-for-stelara-biosimilar Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/fda-adcom-votes-in-favour-of-stealths-barth-syndrome-drug https://spypharm.com/fda-adcom-votes-in-favour-of-stealths-barth-syndrome-drug Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/global-awareness-and-geographic-variations-of-plaque-psoriasis https://spypharm.com/global-awareness-and-geographic-variations-of-plaque-psoriasis Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/roche-wins-first-line-approval-for-pi3k-inhibitor-combo-in-breast-cancer https://spypharm.com/roche-wins-first-line-approval-for-pi3k-inhibitor-combo-in-breast-cancer Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/scholar-rocks-phase-3-sma-trial-achieves-success https://spypharm.com/scholar-rocks-phase-3-sma-trial-achieves-success Fri, 11 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/jj-halts-late-stage-trial-for-bladder-cancer-prospect https://spypharm.com/jj-halts-late-stage-trial-for-bladder-cancer-prospect Fri, 11 Oct 2024 04:00:05 -0400 spectro https://spypharm.com/city-therapeutics-launches-with-135m-series-a-funding https://spypharm.com/city-therapeutics-launches-with-135m-series-a-funding Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/ipsens-elafibranor-gains-mhra-approval-for-pbc-treatment https://spypharm.com/ipsens-elafibranor-gains-mhra-approval-for-pbc-treatment Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/magazine-cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing https://spypharm.com/magazine-cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/could-preventative-care-save-the-future-of-the-nhs https://spypharm.com/could-preventative-care-save-the-future-of-the-nhs Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/emergent-to-donate-20000-narcan-doses-to-fight-opioid-overdoses-ceo-says https://spypharm.com/emergent-to-donate-20000-narcan-doses-to-fight-opioid-overdoses-ceo-says Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/fda-declines-to-approve-zealand-pharmas-hypoglycaemia-therapy-in-infants https://spypharm.com/fda-declines-to-approve-zealand-pharmas-hypoglycaemia-therapy-in-infants Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/purespring-secures-105m-to-start-phase-iii-trial-of-igan-gene-therapy https://spypharm.com/purespring-secures-105m-to-start-phase-iii-trial-of-igan-gene-therapy Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/clinical-dose-companies-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/clinical-dose-companies-in-contract-manufacturing-for-the-pharmaceutical-industry Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/anima-biotechs-machine-learning-programme-reveals-new-mrna-drug-targets https://spypharm.com/anima-biotechs-machine-learning-programme-reveals-new-mrna-drug-targets Thu, 10 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/msd-ventures-into-fibroblast-therapies-with-19bn-deal-with-mestag https://spypharm.com/msd-ventures-into-fibroblast-therapies-with-19bn-deal-with-mestag Thu, 10 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/editas-sells-rights-to-a-licensing-agreement-in-a-57-million-deal https://spypharm.com/editas-sells-rights-to-a-licensing-agreement-in-a-57-million-deal Wed, 09 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/mrna-licensing-agreements-double-with-million-dollar-deals https://spypharm.com/mrna-licensing-agreements-double-with-million-dollar-deals Tue, 08 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/productlife-boosts-drug-development-with-intiquan-acquisition https://spypharm.com/productlife-boosts-drug-development-with-intiquan-acquisition Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/onkure-and-reneo-pharmaceuticals-complete-merger https://spypharm.com/onkure-and-reneo-pharmaceuticals-complete-merger Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/nuhss-cd7-car-t-cell-therapy-shows-promise-for-leukaemia https://spypharm.com/nuhss-cd7-car-t-cell-therapy-shows-promise-for-leukaemia Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/neuvivo-makes-bid-to-enter-als-arena-with-immunotherapy-candidate https://spypharm.com/neuvivo-makes-bid-to-enter-als-arena-with-immunotherapy-candidate Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/ema-starts-review-into-hair-loss-drugs-about-potential-link-to-suicidal-thoughts https://spypharm.com/ema-starts-review-into-hair-loss-drugs-about-potential-link-to-suicidal-thoughts Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/oncolytics-targets-accelerated-approval-for-oncolytic-virus-therapy https://spypharm.com/oncolytics-targets-accelerated-approval-for-oncolytic-virus-therapy Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/activist-investor-starboard-forges-1bn-stake-in-pfizer-to-swing-profits https://spypharm.com/activist-investor-starboard-forges-1bn-stake-in-pfizer-to-swing-profits Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/health-canada-approves-telixs-illuccix-label-expansion https://spypharm.com/health-canada-approves-telixs-illuccix-label-expansion Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/teva-and-mabxience-partner-to-develop-biosimilar-candidate-for-oncology https://spypharm.com/teva-and-mabxience-partner-to-develop-biosimilar-candidate-for-oncology Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/bms-receives-fda-approval-for-opdivo-to-treat-nsclc https://spypharm.com/bms-receives-fda-approval-for-opdivo-to-treat-nsclc Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/resilience-secures-funds-to-enhance-production-of-essential-medicine-components https://spypharm.com/resilience-secures-funds-to-enhance-production-of-essential-medicine-components Sun, 06 Oct 2024 04:00:17 -0400 spectro